Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal Surgery
Key facts
- Who runs it
- DALIM TISSEN Co., Ltd.
- Where
- South Korea3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 130 people enrolled
- Started
- 22 Oct 2024
- Ended
- 18 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CollaStat®
- Floseal®
- Record updated
- 21 January 2026
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- An individual who has voluntarily signed the written consent form for participating in the research as a trial subject
- Patients aged 20 or older
- Patients who are able to participate throughout the entire clinical trial period
- Patient scheduled to have spinal surgery due to spinal stenosis, spinal tumor, injury, etc
- Patients for whom hemostasis is difficult to achieve using standard procedures
- Patients with grade 3 or higher bleeding * Grade 4 or 5 bleeding is reduced to grade 3 by normal procedures (compression, sutures, electrosurgical scalpel, etc.)
Who cannot take part
- Individuals with hypersensitivity to bovine-, porcine-, or animal-derived materials
- Patients with active infections at the surgical site
- Pregnant women or those planning to become pregnant within 1 month after application of the collagen-based hemostat
- Individuals deemed inappropriate for participation by the investigators
- Patients who are using treatments that may affect the test results
- Patients with contraindications to the use of local hemostatic materials
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial evaluates the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery. The study compares this investigational product with an existing hemostatic agent to assess whether it performs equally well in controlling surgical bleeding. Patients with spinal stenosis, tumors, or trauma who require spinal surgery will be enrolled. The hemostat will be applied intraoperatively when grade 3 bleeding is observed. The study aims to determine how well the product works in achieving hemostasis and its safety when it is used during surgery.
The 2 groups in the trial
- Study GroupTreatment being tested
Group applied with CollaStat®
Treatment: Floseal®
- Control GroupExisting treatment, for comparison
Group applied with Floseal®
Treatment: CollaStat®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Clinical Trial to Assess Hemostasis by Applying Collagen-based Thrombin-containing Hemostat in Spinal Surgery
- Record updated
- 21 January 2026